HIMS 0.00%↑ LLY 0.00%↑ NVO 0.00%↑
In Episode 14 of Hims House, host Jonathan Stern is joined by Louis Stevens and Dr. H to discuss the FDA's delayed decision on tirzepatide shortages, its implications for Hims, and how it may reflect on semaglutide. They dive into the importance of anchoring to the long-term vision of Hims amid market volatility and debate the FDA’s growing acknowledgment of the medication shortage. The team also explores the newly launched meal replacement bars and shakes by Hims and their potential impact on the business. They further discuss the market reactions, the diverse weight loss product range, and the integral understanding needed for sustainable growth in the telehealth and wellness space.
00:00 Introduction and Episode Overview
00:30 FDA Decision on Tirzapatide Shortage
01:04 Impact on Hims and Market Reactions
01:35 Review of FDA's Actions and Industry Reactions
05:31 Discussion on Compounded Medications
11:34 Remembering the Long-Term Thesis for Hims
28:58 New Product Launch: Meal Replacement Bars and Shakes
Share this post